NCT00574171View on ClinicalTrials.gov

Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

lapatinib

1250mg by mouth daily one hour before or after breakfast on a continuous basis.

DRUG

Capecitabine

2000mg/m2 of body surface area (BSA), by mouth, divided into twice daily dosing. Capecitabine will be given for days 1 through 14 of a 21 day cycle.

Trial Locations (1)

53792

University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

University of Wisconsin, Madison

OTHER